Brief: Vaccinex Says Had Previously Anticipated Beginning Enrollment In Mid-2020 In Study Of Pepinemab In Alzheimer’S Disease - SEC Filing

Vaccinex

27/03/2020 21:57

March 27 (Reuters) - Vaccinex Inc  VCNX.O :
    * VACCINEX - HAD PREVIOUSLY ANTICIPATED BEGINNING ENROLLMENT
IN
MID-2020 IN STUDY OF PEPINEMAB IN ALZHEIMER’S DISEASE - SEC
FILING
    * VACCINEX - INITIAL ENROLLMENT DATE IS NOW DELAYED IN STUDY
OF
PEPINEMAB IN ALZHEIMER’S DISEASE
    * VACCINEX - EXTENT OF SUCH DELAY IN INITIAL ENROLLMENT DATE
IN
STUDY OF PEPINEMAB IN ALZHEIMER’S DISEASE IS SUBJECT TO
EVALUATING FURTHER DEVELOPMENTS, RISKS RELATED TO COVID-19
    * VACCINEX - ON MARCH 27, CO ENTERED INTO OPEN MARKET SALE
AGREEMENTS WITH JEFFERIES LLC UNDER WHICH CO MAY ISSUE & SELL
SHARES OF COMMON STOCK, PAR VALUE $0.0001/SHARE
    * VACCINEX - ATM OFFERING UNDER OPEN MARKET SALE AGREEMENT
FOR
SALES PRICE OF UP TO $11.5 MILLION
    * VACCINEX - ON MARCH 27, CO ENTERED INTO PURCHASE AGREEMENT
WITH
KEYSTONE CAPITAL PARTNERS
    * VACCINEX - PURSUANT TO PURCHASE AGREEMENT, KEYSTONE HAS
AGREED
TO PURCHASE UP TO $5 MILLION OF COMMON STOCK SUBJECT TO CERTAIN
LIMITATIONS

Source : (https://bit.ly/2ULxQLs)
Further company coverage:  VCNX.O 

 ((Reuters.Briefs@thomsonreuters.com;))